SEC Info - Dyadic International Inc. - ‘8-K’ for 10/27/22

SEC Info℠

Home

Help

Please Sign In

Dyadic International Inc. – ‘8-K’ for 10/27/22

On: Thursday, 10/27/22, at 9:06am ET · For: 10/27/22 · Accession #: 1437749-22-24885 · File #: 1-32513

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

10/27/22  Dyadic International Inc.         8-K:8,9    10/27/22   12:177K                                   RDG Filings/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     28K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     13K 
 7: R1          Document And Entity Information                     HTML     46K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- dyai20221026_8k_htm                 XML     13K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- dyai-20221027_def                XML     37K 
 5: EX-101.LAB  XBRL Labels -- dyai-20221027_lab                     XML     48K 
 6: EX-101.PRE  XBRL Presentations -- dyai-20221027_pre              XML     36K 
 3: EX-101.SCH  XBRL Schema -- dyai-20221027                         XSD     14K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               12±    19K 
12: ZIP         XBRL Zipped Folder -- 0001437749-22-024885-xbrl      Zip     17K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C:

i false i 0001213809 0001213809 2022-10-27 2022-10-27

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (date of earliest event reported): i October 27, 2022

i Dyadic International, Inc.

(Exact name of registrant as specified in its charter)

i Delaware (State or other jurisdiction of incorporation or organization)	i 000-55264 (Commission File Number)	i 45-0486747 (I.R.S. Employer Identification Number)
i 140 Intracoastal Pointe Drive, Suite 404 i Jupiter, i FL i 33477
(Address of principal executive offices and zip code)
( i 561) i 743-8333
(Registrant’s telephone number, including area code)
N/A (Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to Section 12(b) of the Act

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $0.001 per share	i DYAI	The i NASDAQ Stock Market LLC

Item 8.01 Other Events

On October 27, 2022, Dyadic International, Inc. (“Dyadic” or the “Company”) issued a press release announcing that it has received regulatory approval of a Clinical Trial Application (CTA) from the South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial of the DYAI-100 COVID-19 Receptor Binding Domain (RBD) booster vaccine.

A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference, other than the third and fourth paragraphs of the press release.

Item 9.01 Financial Statements and Exhibits
(d) Exhibits
The following exhibit is being filed herein:
Exhibit Number		Description

99.1		Press Release Dated October 27, 2022
104		Cover page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 27, 2022

Dyadic International, Inc.

By:	/s/ *Mark A. Emalfarb*
Name:	Mark A. Emalfarb
Title:	Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	10/27/22	None on these Dates
		List all Filings

↑Top

Filing Submission 0001437749-22-024885 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)